NEW VACCINE Read and be careful.

PETITION UPDATE (12/11/2020)

Dear Elaine,
The COVID vaccine is here.

And, law-abiding, freedom-loving, health conscious people now need genuine information about every aspect of the vaccines which will be rolled out soon.

Especially important are health concerns, freedom concerns and ethical concerns.

Below, please scroll down to find new LifeSite articles grouped under 'Health and Safety', 'Freedom', and 'Ethics' headings.

And, please CLICK HERE https://lifefacts.lifesitenews.com/covid-19/?utm_source=UD_COVID_VAXX&utm_source=LifeSiteNews.com&utm_campaign=e9e476518e-UPDATE-VACCINE-NEWS-12-11-20&utm_medium=email&utm_term=0_12387f0e3e-e9e476518e-408196554

 to access LifeSite's special resources page on COVID-19 Vaccines.

Health and Safety

One of the major concerns regarding the COVID-19 vaccines is whether or not they are actually safe, especially for the elderly or very young people.

The major companies developing vaccines for COVID-19 are rushing through the process, and we do not know all of the side effects. So far, participants in clinical trials have experienced several serious side effects, including “neurological and psychological” breakdowns and “adverse [allergic] reactions.”

Dr. Theresa Deisher, the foundress and chief scientist at the Sound Choice Pharmaceutical Institute, recently told Patrick Coffin that she is very concerned about the manufacturers’ lack of transparency, especially because there have been reports of negative side effects and the companies are not releasing their data to the public.

Additionally, Dr. Kelly Moore of the Immunization Action Coalition told CNN just the other day that COVID-19 vaccines have not been tested on the “frail elderly.” She said that no one should be “alarmed” or “surprised” to hear reports of “multiple people dying” just a day or two after receiving a vaccination against COVID-19.

No one should be compelled to take a COVID-19 vaccine that has untold adverse and concerning side effects.

'Doctor on CNN: Don’t be ‘alarmed’ if elderly die after receiving COVID vaccine' - https://www.lifesitenews.com/news/doctor-on-cnn-dont-be-alarmed-if-elderly-die-after-receiving-covid-vaccine

'COVID-19 ‘warp speed’ vaccines likely not safe and not needed, medical expert says' - https://www.lifesitenews.com/news/covid-19-warp-speed-vaccines-likely-not-safe-and-not-needed-medical-expert-says

'‘Refuse this vaccination’: Acclaimed French doctor unloads on COVID vaccine' - https://www.lifesitenews.com/news/refuse-this-vaccination-acclaimed-paris-doctor-unloads-on-covid-vaccine

'World’s biggest vaccine company sues COVID shot volunteer who spoke about negative side effects' - https://www.lifesitenews.com/news/gates-foundation-backed-covid-vaccine-maker-sues-trial-volunteer-alleging-brain-damage

Freedom Concerns

This vaccine could threaten the freedom of people around the world. And, there have been many indications that even wide-spread vaccination of the populous will not lighten restrictions.

For example, Sir Patrick Vallance, the chief scientist in the U.K. government, said that masks will probably be required until winter 2021 because there is no telling “how good all the vaccines are going to be at preventing the transmission of the virus.”

Additionally, Ontario’s Health Minister has suggested that proof of COVID vaccination will be required to travel, go to work, and even to go to the movie theater.

The vaccine should be voluntary, but will it be required if you want to go anywhere outside the house??

'UK’s chief scientist: Vaccine will not mean ending crushing COVID restrictions' - https://www.lifesitenews.com/news/uks-chief-scientist-vaccine-will-not-mean-ending-crushing-covid-restrictions

'Ontario suggests COVID ‘immunity passport’ for people wanting to travel, go to movies' - https://www.lifesitenews.com/news/ontario-suggests-covid-immunity-passport-for-people-wanting-to-travel-go-to-movies

Ethics Concerns

There are several apparent problems with the vaccines being fast-tracked by HHS’ Operation Warp Speed. One of the vaccines’ major problems is they were tested using aborted fetal cells.

The production and testing of vaccines that use the remains of aborted children, regardless of when they were killed and at what point they were used in the process, is morally unacceptable and must be consistently opposed by the whole pro-life movement.

This type of Frankenscience has no place in a civilized society, certainly not one whose citizens are forced to fund it!

Please READ the following LifeSite exclusive article to find out which vaccines are connected to abortion.

'Which COVID-19 vaccines are connected to abortion?' - https://www.lifesitenews.com/news/which-covid-19-vaccines-are-connected-to-abortion

LIFESITE'S SPECIAL COVID VACCINES RESOURCE PAGE
By signing our petitions and sharing our news stories, you are impacting the cause of Freedom.

Of course, as you know, it is getting more and more difficult for conservatives, Christians and libertarians (especially those who care about medical freedom and vaccines) to communicate and share information with each other.

Therefore, in order to protect our freedom of speech and yours, LifeSite is in the process of migrating away from platforms that tend to censor conservatives (like Facebook, Twitter, and YouTube) to other platforms less prone to censorship, like Parler, Gab and Rumble.

For the time being, we will continue to post on Facebook and Twitter, but we are slowly migrating over to the above-mentioned sites in order to continue our strong - and, uncensored - defense of Freedom, Life, Family and Faith.

If you have an account on Parler, perhaps you might consider following our profile. To do so, please click HERE.

You can also follow us on other platforms, like Gab HERE and Rumble HERE.

Finally, we highly recommend a good news aggregator for conservatives and Christians (and, anyone who cares about freedom): FreeSpeechWire.com

Thank you again for supporting the cause of freedom.

Yours faithfully,

Scott Schittl and the whole Team at LifeSite

PS - If you like the work we do here at LifeSite, please consider making a contribution by CLICK HERE to go to the Donate page. Thank you!

Copyright 2020 LifeSiteNews.com, All rights reserved.
You are receiving this email because you signed up on our website.

Our mailing address is:
LifeSiteNews.com
4 Family Life Lane
Front Royal, Virginia 22630

http://www.humanosphere.org/science/2012/07/the-gates-foundation-connection-to-the-glaxo-drug-fraud-scandal/?fbc

SCIENCE
The Gates Foundation connection to the Glaxo drug fraud scandal
BY TOM PAULSON ON 3 JULY 2012 2
In a ‘landmark’ legal case, the pharmaceutical giant firm GlaxoSmithKline (GSK) pled guilty this week to engaging in fraudulent, criminal behavior which included covering up adverse drug side-effects, promoting ineffective therapies and hiding unfavorable data — and will pay a record $3 billion in fines.

Most news reports quoted GSK’s CEO Andrew Witty blaming the misconduct on others and “a different era for the company,” adding that such behavior will not be tolerated. “I want to express our regret and reiterate that we have learnt from the mistakes that were made.”


Tachi Yamada
Gates Foundation
One of the most high-profile GSK executives alleged to have engaged in misbehavior is Tachi Yamada, former head of global health for the Bill & Melinda Gates Foundation who was before that head of research and development for GSK.

Yamada, while he was head of global health for Gates Fdn, was accused in a U.S. Senate hearing of bullying a scientist to not publish negative findings about a GSK diabetes drug. This was fairly big news at the time and such behavior is part of the federal complaint against the drug firm.

As a journalist blogger, I don’t have as much time as the major news outlets to do a lot of original reporting so I count on the big guns to do the work which I can then plagiarize, uh, I mean ‘curate.’

But so far as I can tell, nobody has made any mention of Yamada’s role in this case. Yet he was pretty high profile — at the center of the controversy surrounding the drug company’s attempt to cover-up adverse side effects of its diabetes drug Avandia.

Here are some of the stories that came out years ago, while he was at the Gates Foundation:

CBS News Meet Glaxo’s Fixer

Guardian Glaxo’s handling of drug Avandia damned by US Senate

ABC News Charity chief accused of bullying critic

Wall Street Journal Glaxo’s criticized for response to critics

Yet none of the news stories about this record-setting case mentions Tachi Yamada.

The only report that comes close (in a sort of through-the-looking-glass way) is this story in Forbes about GSK by Mathew Herper entitled The Terrible Things GlaxoSmithKline Did Wrong — and the Thing It’s Doing Right

Putting aside the redundancy in the Forbes headline (if you do a thing that’s “terrible,” chances are it’s also “wrong”), the gist of the story is a recounting of GSK’s crimes and misdemeanors. Herper appropriately lashes the drug firm, but then like so many news reports goes on to cite GSK CEO Witty blaming the crimes on people ‘who have since left the company’ and notes it is a new era.

And it is GSK’s partnership with the Gates Foundation on trying to develop an effective malaria vaccine that Herper cites as evidence of a new, honest and more open culture at the drug company:

So did Glaxo do anything right? All of the actions predated the tenure of current GlaxoSmithKline chief executive Andrew Witty, who has been trying to improve the company’s reputation. He has pushed forward with efforts to develop medicines for poor nations, including a malaria vaccine that Glaxo is developing with the Bill & Melinda Gates Foundation.

True enough. But how odd to have mentioned GSK-Gates partnership on malaria and left out any mention of the foundation’s former global health chief as one of the key players in this scandal.

So I guess I will remind everybody of this other Gates-GSK connection and leave it (almost) at that.

I will just add that it’s clear to me, as someone who’s covered the Gates Foundation for many years, that Yamada did a lot there to build new bridges between industry and the world of philanthropy. No matter what you think of the drug industry, it has to be a part of the global health program. Somebody has to make (and sell) these drugs and vaccines.

And many would say Yamada did a lot to bring together a somewhat fractured and dispirited global health team at the Seattle philanthropy which had been thrown into disarray by Yamada’s predecessor, Rick Klausner. Klausner had a very different vision for the global health gang — very science-oriented — which didn’t take and ruffled feathers.

Lastly, Yamada, who recently left the Gates Foundation to work for a Japanese drug company, seemed to many a decent and gentle man. We don’t know the whole story behind any of this, of course, and he was clearly just one of many in this historic scandal.

But there’s no getting away that Yamada played a leading role in the largest health fraud case in American history and that, given his much greater influence as head of a philanthropic program that many say sets the agenda for global health, it might be worth mentioning.

Dengue vaccine fiasco leads to criminal charges for researcher in the Philippines

By Fatima ArkinApr. 24, 2019 , 3:55 PM

A prominent pediatrician and medical researcher in the Philippines has been indicted over the failed—and many say premature—introduction of Dengvaxia, a vaccine against dengue that was yanked from the Philippine market in 2017 because of safety issues. If convicted of accusations leveled at her by the national Department of Justice (DOJ), Rose Capeding, 63, former head of the dengue department of the Research Institute for Tropical Medicine (RITM) here, could face up to 48 years in prison.
In February, prosecutors concluded there is probable cause to indict Capeding and 19 others for "reckless imprudence resulting [in] homicide," because they "facilitated, with undue haste," Dengvaxia's approval and its rollout among Philippine schoolchildren.
Capeding, through her family, declined to comment, but her son Juhani Capeding says his mother "couldn't have imagined" that submitting research to top medical journals could have led to "this point." Some of Capeding's colleagues agree. "As a scientist, I really feel so disgusted, dismayed, [and] heartbroken about the whole situation," says Lulu Bravo, executive director of the Philippine Foundation for Vaccination here.

SIGN UP FOR OUR DAILY NEWSLETTER

Get more great content like this delivered right to you!



Also charged are Capeding's former boss, former RITM head Socorro Lupisan; former Department of Health (DOH) Secretary Janette Garin; other officials at DOH and the Philippines Food and Drug Administration (FDA); and current and former officials of Sanofi Pasteur, the French company producing the shots. The first of eight criminal cases—which could be consolidated—are now pending in five courts throughout the northern island of Luzon, where the vaccination campaign took place.
Dengvaxia consists of an attenuated yellow fever virus that expresses genes of each of the four types of dengue virus. The Philippine FDA greenlighted the vaccine in December 2015, based on research funded by Sanofi Pasteur in which Capeding played an important role. For example, she was the first author on a 2014 paper in The Lancet detailing a study among more than 10,000 children in five Asian countries that showed Dengvaxia worked and had a good safety profile. In April 2016, the Philippine government launched a $67 million public school–based immunization program for Dengvaxia.
That alarmed some scientists, because the dengue virus is peculiar: A first infection is rarely fatal, but a second one with a different virus type can lead to much more serious disease, because of what is called antibody-dependent enhancement (ADE), in which the immune response to the first virus amplifies the effect of the second type. Scott Halstead, a retired dengue expert formerly at the Uniformed Services University of the Health Sciences in Bethesda, Maryland, argued that dengue vaccines could have the same effect, and warned that Dengvaxia should not be given to children never infected with dengue. But a vaccine panel at the World Health Organization (WHO) concluded in 2016 that Dengvaxia was safe for children aged 9 and older.
Halstead's concerns proved valid. In November 2017, Sanofi Pasteur announced that the vaccine could indeed exacerbate cases of dengue in children never previously infected, and the Philippines halted the campaign immediately. (WHO now recommends the vaccine be used only after a test to be sure children have had at least one brush with dengue.)
The news enraged and frightened the parents of some 830,000 schoolchildren who had already received one or more Dengvaxia shots. Given the high prevalence of dengue in the Philippines, most probably already had the disease at least once, and thus are not at risk of ADE—but some had not. In September 2018, DOH Undersecretary Enrique Domingo told reporters that 130 vaccinated children had died; 19 of those had dengue, meaning ADE possibly played a role. The case triggered "mass hysteria," says Edsel Salvaña, an infectious disease physician at the University of the Philippines here. "Parents thought their kids were all going to die."
What prosecutors think Capeding—or any of the other accused—is responsible for remains unclear, because the full report about the case has not yet been released. But other scientists have come to Capeding's defense. "[If] you're going to say that a scientist doing a clinical trial is actually liable for anything bad that happens once the product is approved, then that's just crazy," Salvaña says. "The indictment of Rose Capeding is an egregious, unjust, and highly disturbing act," adds Tikki Pangestu, a Singapore-based adviser to the Asia Dengue Vaccine Advocacy Group who has written policy and advocacy papers with Capeding.
But Halstead says the trials Capeding helped conduct were not well designed; if the researchers had looked separately at outcomes for children who did and didn't have dengue before the shot, they would have identified the ADE risk, he says. He notes that Sanofi and WHO committees designed the trials, however, not Capeding. He declined to say whether criminal charges are warranted: "This is a very complex ethical and scientific question that needs to be handled carefully."
Sanofi, in a statement to Science, says the company "strongly disagrees with the DOJ's findings made against its officials (current and past) and we will vigorously defend them." It's not yet clear when the criminal trials will start.
*Correction, 6 June, 2 p.m.: An earlier version of this story suggested Halstead is still affiliated with the Uniformed Services University of the Health Sciences. 

Posted in: 

• Health
  
• Scientific Community
  

https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-to-join-forces-in-unprecedented-vaccine-collaboration-to-fight-covid-19/?fbclid=IwAR3xPC40BAIlnA6eIkaxfXcvJSVOaUM-PWuPoh-fsCLNi0-c9NXbXhnY-Ls
14 April 2020

Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
For media and investors only

Issued: London, UK

Companies to combine innovative technologies to develop an adjuvanted COVID-19 vaccine 
Candidate vaccine expected to enter clinical trials in the second half of 2020 and, if successful, to be available in the second half of 2021
Sanofi and GSK today announce that they have signed a letter of intent to enter into a collaboration to develop an adjuvanted vaccine for COVID-19, using innovative technology from both companies, to help address the ongoing pandemic.

Sanofi will contribute its S-protein COVID-19 antigen, which is based on recombinant DNA technology. This technology has produced an exact genetic match to proteins found on the surface of the virus, and the DNA sequence encoding this antigen has been combined into the DNA of the baculovirus expression platform, the basis of Sanofi’s licensed recombinant influenza product in the US.

GSK will contribute its proven pandemic adjuvant technology to the collaboration. The use of an adjuvant can be of particular importance in a pandemic situation since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and therefore contributing to protect more people. 

Paul Hudson, CEO Sanofi, said: “As the world faces this unprecedented global health crisis, it is clear that no one company can go it alone. That is why Sanofi is continuing to complement its expertise and resources with our peers, such as GSK, with the goal to create and supply sufficient quantities of vaccines that will help stop this virus.”

Emma Walmsley, CEO GSK, said: “This collaboration brings two of the world’s largest vaccines companies together. By combining our science and our technologies, we believe we can help accelerate the global effort to develop a vaccine to protect as many people as possible from COVID-19.”

The combination of a protein-based antigen together with an adjuvant, is well-established and used in a number of vaccines available today. An adjuvant is added to some vaccines to enhance the immune response, and has been shown to create a stronger and longer lasting immunity against infections than the vaccine alone. It can also improve the likelihood of delivering an effective vaccine that can be manufactured at scale. 

The companies plan to initiate phase I clinical trials in the second half of 2020 and, if successful and subject to regulatory considerations, aim to complete the development required for availability by the second half of 2021. 

As previously announced by Sanofi, development of the recombinant-based COVID-19 vaccine candidate is being supported through funding and a collaboration with the Biomedical Advanced Research and Development Authority (BARDA), in the US. The companies plan to discuss funding support with other governments and global institutions prioritising global access.

BARDA Director, Rick A. Bright, Ph.D., said: “Strategic alliances among vaccine industry leaders are essential to make a coronavirus vaccine available as soon as possible. Development of the adjuvanted recombinant-based COVID-19 vaccine candidate holds the potential to lower the vaccine dose to provide vaccine to a greater number of people to end this pandemic, and help the world become better prepared or even prevent future coronavirus outbreaks.”

The companies have set up a Joint Collaboration Task Force, co-chaired by David Loew, Global Head of Vaccines, Sanofi and Roger Connor, President Vaccines, GSK. The taskforce will seek to mobilise resources from both companies to look for every opportunity to accelerate the development of the candidate vaccine.

Considering the extraordinary humanitarian and financial challenge of the pandemic, both companies believe that global access to COVID-19 vaccines is a priority and are committed to making any vaccine that is developed through the collaboration affordable to the public and through mechanisms that offer fair access for people in all countries.

This new collaboration marks a significant milestone in Sanofi’s and GSK’s ongoing contributions to help fight COVID-19. The companies have entered into a Material Transfer Agreement to enable them to start working together immediately. Definitive terms of the collaboration are expected to be finalised over the next few weeks.

About Sanofi
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe. Sanofi, Empowering Life.

About GSK
GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com/about-us.

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Principal risks and uncertainties' in the company's Annual Report on Form 20-F for 2019.